The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. (Q38792331)

6 September 2017

title

The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. (English)

1 reference

6 September 2017

1 reference

Ya-Tian Chen

1

1 reference

6 September 2017

Feng Zhu

2

1 reference

6 September 2017

Wei-Ren Lin

3

1 reference

6 September 2017

Rong-Biao Ying

4

1 reference

6 September 2017

You-Ping Yang

5

1 reference

6 September 2017

Ling-Hui Zeng

6

1 reference

6 September 2017

publication date

22 February 2016

1 reference

Cancer Chemotherapy and Pharmacology

6 September 2017

published in

1 reference

6 September 2017

volume

77

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

757-765

1 reference

Update of research on the role of EZH2 in cancer progression

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

EZH2: biology, disease, and structure-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Ascorbic acid uptaken by sodium-dependent vitamin C transporter 2 induces βhCG expression through Sp1 and TFAP2A transcription factors in human choriocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Theranostic potential of oncolytic vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Activated p53 suppresses the histone methyltransferase EZH2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2990-1

10.1007/S00280-016-2990-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1010211898

0 references

1 reference